AstraZeneca PLC

Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
Returns
Key stats
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Financials
About AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Others were interested in
See all stocksFrequently asked questions
To buy AstraZeneca PLC stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for AstraZeneca PLC by name or ticker, choose the number of shares, and place your order.
The ticker symbol for AstraZeneca PLC is AZN:xlon. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
AstraZeneca PLC has its primary listing on London Stock Exchange. You can trade AstraZeneca PLC with a Saxo account, alongside thousands of other stocks worldwide.
Yes, AstraZeneca PLC is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include AstraZeneca PLC as part of a broader investment portfolio.